Zenas BioPharma Engages with Investors at Upcoming Conferences
WALTHAM, Mass – Zenas BioPharma, Inc. (Nasdaq: ZBIO) is excited to announce its participation in a series of notable healthcare investor conferences. As a clinical-stage biopharmaceutical company, Zenas is dedicated to developing transformative therapies that primarily focus on immunology, and these events present a valuable opportunity to connect with investors and share insights on our progress.
Healthcare Investor Conference Schedule
Participating conferences include:
Healthcare Innovation Conference
The first event on the calendar is Guggenheim’s inaugural Healthcare Innovation Conference. This conference is set to happen soon, allowing the Zenas team to engage with industry professionals and investors alike.
International Presence at Jefferies London Healthcare Conference
Another significant venue will be the Jefferies London Healthcare Conference, where Zenas will present crucial information about its innovations and strategies on a global stage, enhancing its visibility among European investors.
Citi’s Global Healthcare Conference
Next, Zenas will take part in Citi’s 2024 Global Healthcare Conference. This global conference will allow the company to showcase its advancements and plans directly to a wide audience of healthcare specialists and potential investors.
HealthCONx Conference Insights
Lastly, Zenas will appear at the Evercore ISI HealthCONx Conference. Each presentation will provide listeners with an in-depth look at Zenas' strategic direction, emphasizing how the company aims to be a front-runner in developing innovative therapies for autoimmune diseases.
Webcasts and Presentations
For those unable to attend in person, live webcasts and archived presentations will be accessible. Interested parties can find these resources in the Events and Presentations section of the Zenas BioPharma website.
About Zenas BioPharma, Inc.
As a clinical-stage global biopharmaceutical company, Zenas BioPharma is committed to making significant strides in immunology-based therapies aimed at improving the quality of life for patients. Zenas prides itself on its experienced leadership and an effective product acquisition strategy that drives innovation in treating autoimmune diseases.
Leading Product Candidate
The company’s lead product candidate, obexelimab, stands out as a bifunctional monoclonal antibody targeting both CD19 and Fc?RIIb. This innovative drug is designed to inhibit the activity of pathogenic B cells while preserving the overall immune system functionality, representing a significant advancement in the treatment of chronic autoimmune conditions.
Global Impact and Commitment
Zenas BioPharma envisions addressing the clinical needs of patients living with autoimmune diseases through cutting-edge science and dedicated research. With a strong focus on product development and a clear pathway to commercialization, Zenas is arming itself with the tools necessary to revolutionize patient care.
Investor Contact Information
If you would like to reach out to Zenas regarding investment opportunities, please contact:
Matthew Osborne
Investor Relations and Corporate Communications
Email: Matt.osborne@zenasbio.com
Frequently Asked Questions
What type of company is Zenas BioPharma?
Zenas BioPharma is a clinical-stage global biopharmaceutical company focused on developing immunology-based therapies.
Where will Zenas be presenting its information?
Zenas will be participating in multiple healthcare investor conferences, including those hosted by Guggenheim and Jefferies.
What is obexelimab?
Obexelimab is Zenas’ lead product candidate, designed to treat autoimmune diseases without depleting B cells in the immune system.
How can I access Zenas' presentations?
Live webcasts and archived recordings of Zenas’ presentations will be available in the Events and Presentations section of their website.
Who can I contact for investor inquiries?
For investor relations, please contact Matthew Osborne via email at Matt.osborne@zenasbio.com.